Novo Nordisk closes Dicerna acquisition deal

Novo Nordisk has completed the acquisition of Dicerna Pharmaceuticals, which is the Danish firm's biggest acquisition so far.

Photo: Tidsvilde Stine/Ritzau Scanpix

Novo Nordisk has closed the acquisition deal of Dicerna Pharmaceuticals, with which the Danish firm has collaborated to develop potential RNA drugs since 2019, Novo Nordisk announces in a press release on Tuesday.

Shares of Dicerna, which is based in Boston, have been purchased at a price of USD 38.25 dollars apiece, equating to USD 3.3bn, making this Novo Nordisk's single-biggest buy ever.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs